Ventfort®
The biologically active food supplement VENTFORT® contains a complex of low molecular weight
peptides with a molecular weight of up to 5000 Da, extracted from the tissue of the vessels (aorta) of
young animals - calves up to 12 months of age or pigs.
VENTFORT® is available in tablets or capsules with an active ingredient content of 10 mg.
Experimental studies have shown that peptides have a tissue-specific effect on the cells of those tis-
sues from which they are isolated. They improve the tropism of the cells of the tissues of the vascular
wall and have a regulatory effect on metabolic processes in them, contribute to the normalization of
functional and morphological changes in the vascular wall, regulate the content of cholesterol and
lipoproteins in the blood, reducing the risk of various vascular diseases. This suggests the effective-
ness of the use of VENTFORT® for the restoration of vascular function in various conditions, includ-
ing vascular atherosclerosis.
Atherosclerosis and its consequences are one of the leading causes of disability and death in devel-
oped countries. Changes in the vascular wall that increase with age and impaired hemodynamics lead
to decreased peripheral blood circulation, vascularization of organs and tissues, the development of
various components of oxygen deficiency, and trophic disorders (2, 3, 4, 6).
Drug treatment of atherosclerosis aims to normalize lipid metabolism, blood coagulation, and metab-
olism in the vascular wall (1, 5).
Medicines that normalize cholesterol and β-lipoprotein levels:
- Drugs, which prevent the absorption of cholesterol in the intestine (cholestyramine, β-sitosterol,
diosponin, polisponin);
- Drugs, which interrupt the synthesis of cholesterol in the body (clofibrate, miscleron, regardin, cet-
amifen, nicotinic acid, vitamin PP);
- Drugs, which enhance the splitting and excretion of cholesterol from the body (linetol, arachidene).
- Drugs, which improve microcirculation, normalize vascular permeability, reduce swelling of vascular
tissues and improve metabolic processes in the vascular wall (prodectin, dicinone, doxium, glivenol,
escuzan, etc.)
Clinical trials of VENTFORT® took place at the Medical Center of the Saint Petersburg Institute of
Bioregulation and Gerontology of the Northwest Branch of the Russian Academy of Medical Sciences
in patients with atherosclerosis of various arteries and senile purpura in the period from November
2005 to February 2006.
CLINICAL CHARACTERISTICS OF PATIENTS
The clinical trials involved 49 patients with atherosclerosis of the arteries and senile purpura, 27 of
whom made up the primary group (15 men, 12 women) - in addition to conventional drugs, they took
VENTFORT® orally 10-15 minutes before meals, 1-2 capsules 2-3 times a day for 10-15 days, de-
pending on the severity of the pathological process. Another 22 patients (11 men, 11 women) included
in the control group were prescribed only general-purpose drugs. The age of patients in both groups
ranged from 52 to 84 years (Table 1).
Patients of both groups had different clinical symptoms depending on the lesions of vessels of varying
caliber: hypertension, coronary heart disease, cerebrovascular disorders with impaired memory, con-
centration, and affective lability. All patients showed progressive dynamics of disease development.
All patients previously received symptomatic and pathogenetic therapy for specific clinical symptoms
of vascular pathology.
Для таблиц, дозировок и примечаний сверяйтесь с оригинальным PDF: при извлечении текста порядок колонок может измениться.
Из библиотеки Peptides. Авторство и содержание оригинала сохранены. Размещено с разрешения поставщика.